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Letters 
To the Editor: 
The recent articles by Khaja, et al (1) and Anderson, et al 
(2) constitute a significant contr ibut ion to the expe-
rience with thrombolyt ic therapy in the management of 
acute evolving myocardial infarction. However, other 
reports consistent wi th these trials yielded disparate 
results and conclusions. The data presented by Ander-
son, et al (2) suggest favorable effects of streptokinase, 
but there are methodological problems: inclusion of 
subjects who had subtotal occlusion o f the infarct artery, 
and random assignment of control patients to routine 
cardiac care unit management wi thout angiographic 
characterization of coronary anatomy. In an accompany-
ing editorial (3), Swan suggests that the t ime interval 
between the onset of chest pain and intervention wi th 
streptokinase may be the critical variable to explain the 
seemingly inconsistent findings in these two studies. This 
suggestion, which has been made previously (4), seems 
to be inconsistent wi th reports that streptokinase ther-
apy is effective after mean times of 5.6 ± 4 hours (5) and 
9.2 ± 4 hours (6). 
Comparison with results f rom previous investigations is 
complicated by the use of dif ferent doses, routes, and 
times of administration of streptokinase (5-8), varied 
usage and modes of administration of anticoagulant 
therapy (5-8) and by occasional use of corticosteroids 
and plasminogen (7). Earlier trials lacked randomization 
and prospective controls (5-7); however, in even more 
recent studies selected patient groups were so dissimilar 
that valid comparisons were impossible. 
An association has been demonstrated between spasm 
and the site of significant coronary stenoses (9). How 
does this observation relate to subjects wi th total versus 
subtotal coronary occlusion? 
The occurrence of hemorrhagic myocardial infarction 
after successful reperfusion has been described both in 
experimental animal studies (10) and in humans (11). 
That this phenomenon may promote delayed infarct 
healing, increase susceptibility to rupture and aneurysm 
format ion, and lead to infarct extension (10) merits con-
cern (12). Could streptokinase be replacing an ischemic, 
" b l a n d " infarct wi th a hemorrhagic one? If so, would it 
account for the absence of benefit in ventricular func-
t ion after therapy? 
Streptokinase is an effective agent for producing reper-
fusion through an occluded infarct artery. Its effect on 
the ischemic myocardium, however, is less well estab-
lished. Identifying the clinical, laboratory, and angio-
graphicfeatures of patients likely to benefit f rom throm-
bolytic therapy is essential. Only rigorously designed, 
randomized trials with standardized protocols will resolve 
these crucial questions: Can streptokinase favorably 
influence infarct size wi thout unnecessary potential risk? 
If so, what is its optimal t iming and route of administra-
tion? What other therapeutic agents (e.g., nitrates, beta-
blockers, calcium antagonists, anti-platelet drugs) can be 
combined with streptokinase for additional benefit? 
What are the long-term effects of successful reperfu-
sion; and are there definite end-points indicating advan-
tage or detriment? After successful reperfusion, what 
form of management is best to treat the remaining coro-
nary artery disease? What is the optimal t ime for such 
intervention? 
We agree with the dictum of Leroy and Snider (13) that 
"suspicion rather than certainty should govern the phy-
sician's conduct . " Widespread application of thrombo-
lyt ictherapy to acute myocardial infarction should await 
further demonstration of its unequivocal benefit. 
David M. Lang, M D 
Jan Rival, M D 
Department of internal Medicine, 
Henry Ford Hospital 
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